Advanced oxidation protein products as a novel molecular basis of oxidative stress in uraemia

Nephrology Dialysis Transplantation

Volumn 14, Issue SUPPL. 1, 1999, Pages 76-78

  Witko Sarsat, Véronique ^a   Nguyen Khoa, T ^a   Jungers, P ^a   Drueke T B ^a   Descamps Latscha, B ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MYELOPEROXIDASE; PROTEIN; REACTIVE OXYGEN METABOLITE; SERUM ALBUMIN;

CHRONIC KIDNEY FAILURE; CONFERENCE PAPER; HEMODIALYSIS; HUMAN; MOLECULAR WEIGHT; MONOCYTE; NEUTROPHIL; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; UREMIA;

EID: 0032893391     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/14.suppl_1.76     Document Type: Conference Paper

References (23)

1. Descamps-Latscha B. The immune system in end-stage renal disease. Curr Opin Nephrol Hypertens 1993; 2: 883-891
2. Descamps-Latscha B, Witko-Sarsat V, Junger P. Infection and immunity in end-stage renal disease patients. In: Henrich, WI ed. The principles and practice of nephrology. Williams and Wilkins, Baltimore, MD
3. Pereira BJG, Shapiro L, King AJ, Falagas ME, Strom JA, Dinarello CA. Plasma levels of IL-1 beta, TNF-alpha and their specific inhibitors in undialyzed chronic renal failure. CAPD and hemodialysis patients. Kidney Int 1994; 45: 890-896
4. Descamps-Latscha B, Herbelin A, Nguyen AT et al. Balance between IL-1 beta. TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationships with activation markers of T cells, B cells, and monocytes. J Immunol 1995; 154: 882-892
5. Nguyen AT, Lethias C, Zingraff J, Herbelin A, Naret C, Descamps-Latscha B. Hemodialysis membrane-induced activation of phagocyte oxidative metabolism detected in vivo and in vitro within microamounts of whole blood. Kidney Int 1985; 28: 158-167
6. Himmelfarb J, Lazarus JM, Hakim R. Reactive oxygen species production by monocytes and polymorphonuclear leukocytes during dialysis. Am J Kidney Dis 1991; 17: 271-276
7. Loughrey CM, Young IS, Lightbody JH, McMaster D, McNamee PT, Trimble ER. Oxidative stress in haemodialysis. Q J Med 1994; 87: 679-683
8. Céballos-Picot I, Witko-Sarsat V, Mérad-Boudia M et al. Glutathione antioxidant system as a marker of uremia progression and oxidative stress in chronic renal failure. Free Rad Biol Med 1996; 21: 845
9. Wolff SP, Garner A, Dean RT. Free radicals, lipids and protein degradation. Trends Biochem Sci 1986; 11: 27-31
10. Davies KJ. Protein damage and degradation by oxygen radicals. I. General aspects. J Biol Chem 1987; 262: 9895
11. Witko-Sarsat V, Friedlander M, Capeillère-Blandin C et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996; 49: 1304-1313
12. Makita Z, Bucala R, Rayfield EJ et al. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet 1994; 343: 1519-1522
13. Friedlander MA, Witko-Sarsat V, Nguyen AT et al. The advanced glycation endproduct pentosidine and monocyte activation in uremia. Clin Nephrol 1996; 45: 379
14. Heinecke JW, Li W, Daehnke H, Goldstein JA. Dityrosine, a specific marker of oxidation, is synthesized by the myeloperoxidase-hydrogen peroxide system of human neutrophils and macrophages. J Biol Chem 1993; 268: 4069-4077
15. Miyata T, Wada Y, Cai Z et al. Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Kidney Int 1997; 51: 1170-1181
16. Schmidt AM, Hori O, Chen JX et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 1995; 96: 1395-1403
17. Miyata T, Inagi R, Iida Y et al. Involvement of beta 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-alpha and interleukin-1. J Clin Invest 1994; 93: 521-1094
18. Vlassara H, Moldawer L, Chan B. Macrophage/monocyte receptor for nonenzymatically glycosylated protein is upregulated by cachectin/tumor necrosis factor. J Clin Invest 1989; 84: 1813-1820
19. Witko-Sarsat V, Friedlander M, Nguyen-Khoa T et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998; 161: 2524-2532
20. Daugherty A, Dunn JL, Rateri DL, Heinecke JW. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 1994; 94: 437-444
21. Anderson MM, Hazen SL, Hsu FF, Heinecke JW. Human neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride system to convert hydroxy-amino acids into glycoaldehyde, 2-hydroxypropanal, and acrolein. A mechanism for the generation of highly reactive alpha-hydroxy and alpha, beta-unsaturated aldehydes by phagocytes at sites of inflammation. J Clin Invest 1997; 99: 424-432
22. Witko-Sarsat V, Nguyen-Khoa T, Canteloup S et al. Advanced oxidation protein products (AOPP) as novel mediators between neutrophils and monocytes in chronic renal failure (CRF). J Am Soc Nephrol 1997; 8: 488A
23. Witko-Sarsat V, Descamps-Latscha B. Advanced oxidation protein products: novel uraemic toxins and proinflammatory mediators in chronic renal failure? Nephrol Dial Transplant 1997; 12: 1310-1311